Autoimmune‐prone (NZW × BXSB)F1 (W/BF1) mice escape severe thrombocytopenia after treatment with deoxyspergualin, an immunosuppressant

Summary. Male (NZW × BXSB)F1 mice spontaneously develop a disease which closely resembles human systemic autoimmune disease, involving idiopathic thrombocytopenic purpura and glomerulonephritis. We investigated whether autoimmune thrombocytopenia in the mice responded to deoxyspergualin, as immunosuppressant. Deoxyspergualin completely prevented the development of thrombocytopenia and suppressed the increase in circulating autoantibodies against platelets. This agent also ameliorated lupus nephritis. These findings suggest that deoxyspergualin may be effective in the prevention of idiopathic thrombocytopenic purpura.

[1]  N. Masauzi,et al.  15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease after allogeneic bone marrow transplantation. , 1994, Bone marrow transplantation.

[2]  F. Abe,et al.  Therapeutic studies of the combination of deoxyspergualin and prednisolone in MRL/lpr mice with advanced lupus-like disease. , 1994, The Journal of antibiotics.

[3]  R. Engelman,et al.  Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice. , 1993, Blood.

[4]  Y. Tsukamoto,et al.  15‐DEOXYSPERGUALIN “RESCUE THERAPY” FOR METHYLPREDNISOLONE‐RESISTANT REJECTION OF RENAL TRANSPLANTS AS COMPARED WITH ANTI‐T CELL MONOCLONAL ANTIBODY (OKT3) , 1993, Transplantation.

[5]  J. Najarian,et al.  Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin , 1993, The Lancet.

[6]  S. Nadler,et al.  Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. , 1992, Science.

[7]  K. Morikawa,et al.  THE SUPPRESSIVE EFFECT OF DEOXYSPERGUALIN ON THE DIFFERENTIATION OF HUMAN B LYMPHOCYTES MATURING INTO IMMUNOGLOBULIN‐PRODUCING CELLS , 1992, Transplantation.

[8]  F. Abe,et al.  Therapeutic activity of deoxyspergualin in comparison with cyclosporin A, and its combined use with cyclosporin A and prednisolone in highly allogeneic skin transplantation in the rat. , 1992, Agents and actions.

[9]  S. Honda,et al.  Effects of Splenectomy on Immune Thrombocytopenic Purpura in (NZW x BXSB) F1 Mice: Analyses of Platelet Kinetics and Anti-Platelet Antibody Production , 1992, Thrombosis and Haemostasis.

[10]  J. Talmadge,et al.  Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. , 1992, International journal of immunopharmacology.

[11]  S. Honda,et al.  Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1. , 1992, Blood.

[12]  F. Abe,et al.  Deoxyspergualin in lethal murine graft-versus-host disease. , 1991, Transplantation.

[13]  F. Reinholt,et al.  Deoxyspergualin for liver graft rejection , 1990, The Lancet.

[14]  Y. Tomiyama,et al.  Analyses of thrombocytopenia in idiopathic thrombocytopenic purpura-prone mice by platelet transfer experiments between (NZW x BXSB)F1 and normal mice. , 1990, Blood.

[15]  K. Dohi,et al.  A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. , 1990, Transplantation.

[16]  T. Tokunaga,et al.  Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. , 1989, Immunology.

[17]  T. Aoyagi,et al.  Lupus nephropathy in New Zealand F1 hybrid mice treated by (-)15-deoxyspergualin. , 1988, Kidney international.

[18]  Teruya Nakamura,et al.  Biological activities of deoxyspergualin in autoimmune disease mice. , 1988, The Journal of antibiotics.

[19]  S. Nomura,et al.  (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura , 1988, The Journal of experimental medicine.

[20]  T. Aoyagi,et al.  Immunosuppressive activities of deoxyspergualin. I. Effect of the long-term administration of the drug on the development of murine lupus. , 1987, Immunopharmacology.

[21]  T. Aoyagi,et al.  Immunosuppressive activities of deoxyspergualin. II. The effect on the antibody responses. , 1987, Immunopharmacology.

[22]  T. Takeuchi,et al.  Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. , 1985, The Journal of antibiotics.

[23]  J. Pizzuto,et al.  Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. , 1984, Blood.

[24]  H. Naganawa,et al.  A new antitumor antibiotic, spergualin: isolation and antitumor activity. , 1981, The Journal of antibiotics.

[25]  S. Izui,et al.  (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction , 1981, The Journal of experimental medicine.